SecBot SecBot
PRESS-RELEASE ·Filed May 8, 2026

DRTS

Alpha Tau Medical Ltd.
BULLISH
Impact 7/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The completion of enrollment is a positive catalyst, but the stock may have already priced in this milestone. Watch for data readouts and PMA submission progress. Approval is not guaranteed; monitor for any delays or negative data.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$8.51
T+0 close · May 8, 2026 · via day close
Latest settled
+53.70%
T+60 · $13.08
Vs SPY
+48.86%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 8 $8.51entry
  2. T+1 · 6mo ago +21.50%α +21.27% · $10.34
  3. T+5 · 6mo ago +22.33%α +20.86% · $10.41
  4. T+20 · 5mo ago +9.87%α +9.85% · $9.35
  5. T+60 · 3mo ago +53.70%α +48.86% · $13.08
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alpha Tau completed enrollment in its ReSTART pivotal trial (88 patients) for Alpha DaRT in recurrent cutaneous squamous cell carcinoma, a key step toward FDA PMA approval. The company has Breakthrough Device Designation and submitted the first PMA module in January 2026. This milestone de-risks the regulatory pathway but approval and commercialization remain uncertain.

Key Facts

  • Completed enrollment of 88 patients in ReSTART pivotal trial for recurrent cSCC.
  • First U.S. pivotal study for Alpha Tau to complete enrollment.
  • Alpha DaRT has FDA Breakthrough Device Designation for this indication.
  • First module of modular PMA application submitted in January 2026.
  • cSCC is the second most common skin cancer with rising incidence and unmet need.
  • Trial co-primary endpoints: objective response rate and duration of response at 6 months.

Financial Impact

No financial figures disclosed; potential future revenue from FDA approval in cSCC, but timeline and market size not quantified.

Risk Factors

  • FDA may not approve PMA; clinical data may not meet endpoints.
  • Competition from existing and emerging therapies for cSCC.
  • Company has limited operating history and needs additional funding.
  • Stock may have already priced in this milestone; limited upside from here.

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
80% bullish (10 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3291075

US Market Status

Market Closed · Opens in 9h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 8, 2026